• G. SAI KIRAN The Institution: Nirmala College of Pharmacy
  • N. DOONDI PHANI KUMAR The Institution: Nirmala College of Pharmacy



Rare cancers, Cytotoxic therapy, Antibiotic utilization


Objective: Rare cancers are creating a massive challenge to the world. It has associated with genetic mutations or socio-environmental factors, which includes genes, smoking, alcohol, ionizing radiation exposure, organic-inorganic chemicals, air and water pollution, viruses, and bacteria. When 15 cases per 1,00,000 people per year, we can consider it as a rare case as per the National Cancer Institute

This study aim is the importance of antibiotics in various unique metastasis along with cytotoxic therapy at tertiary care hospital.

Methods: The inclusion criteria of our study include a person who is suffering from rare metastasis at an early stage. We excluded the data that are those who are suffering from the typical type of cancers, multiple co-morbid conditions. This study was carried out the Prospective Cohort Study conducted between June 2018 to March 2020.

Results: Number of 20 rare cancers we consider for final analysis, the overall antibiotics use in this study 18 antibiotics they prescribed in overall cases, prescribed cytotoxic drugs are 23. the chi-square test value is P=0.001, the confidence interval(CI) is 95%, the likelihood ratio is 54.4, odd’s ratio is 2.0(CI 95%, P=0.711), Male patients more than the female patients.

Conclusion: Cancer is a complex disorder, which is occurred through gene proliferation and socio-environmental factors. Rare metastasis is challenging to physicians and patients, however as per our observation, cytotoxic therapy with antibiotics can reduce the risk of rare metastasis and as well improved therapeutic adhesion, and we need clear supporting evidence on it through clinical trials.


Download data is not yet available.


1. Pillai RK, Jayasree K. Rare cancers: challenges and issues. Indian J Med Res 2017;145:17.
2. Parsa N. Environmental factors inducing human cancers. Iran J Public Health 2012;41:1-9.
3. Gospodarowicz M, Trypuc J, Cruz AD, Khader J, Omar S, Knaul F. Cancer services and the comprehensive cancer center. Third Edition. Vol, 3. Disease Control Priorities; 2015. p. 195.
4. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 2014;4:a014282.
5. Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, et al. The burden of cancers and their variations across the states of India: the global burden of disease study 1990–2016. Lancet Oncol 2018;19:1289-306.
6. Smith RD, Mallath MK. History of the growing burden of cancer in India: from antiquity to the 21st century. J Global Oncol 2019;5:1-15.
7. DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States. CA: A Cancer J Clinicians 2017;67:261-72.
8. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancer Med Sci 2019;13:961.
9. Nurgali K, Jagoe RT, Abalo R. Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Frontiers Pharmacol 2018;9:245.
10. Alibek K, Bekmurzayeva A, Mussabekova A, Sultankulov B. Using antimicrobial adjuvant therapy in cancer treatment: a review. Infectious Agents Cancer 2012;7:33.
11. Staber P, Langner S, Dornbusch HJ, Neumeister P. Antifungal management in cancer patients. Wiener Medizinische Wochenschrift 2007;157:503-10.
12. University. MCoGaA. Antibiotics may impact cancer treatment efficacy. Sci Daily; 2018.
13. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infection and drug resistance. 2018;11:1645-58.
14. Biocompare. Antibiotics may be key to boosting pancreatic cancer treatment. Thursday; 2018.
15. Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, et al. An update on burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Into Imaging 2019;10:56.
16. Pannone G, Zamparese R, Pace M, Pedicillo MC, Cagiano S, Somma P, et al. The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based survey. Infectious Agents Cancer 2014;9:34.
17. Biswas B, Bakhshi S. Management of ewing sarcoma family of tumors: current scenario and unmet need. World J Orthopedics 2016;7:527-38.
18. Wilms Tumor-Childhood: Introduction; 2019. [Last accessed on 20 Mar 2019]



How to Cite

KIRAN, G. S., and N. D. P. KUMAR. “THE IMPORTANCE OF ANTIBIOTICS IN A VARIOUS UNIQUE METASTASIS ALONG WITH CYTOTOXIC THERAPY AT TERTIARY CARE HOSPITAL: A PROSPECTIVE COHORT STUDY”. International Journal of Current Pharmaceutical Research, vol. 12, no. 4, July 2020, pp. 41-44, doi:10.22159/ijcpr.2020v12i4.39048.



Original Article(s)